Related Experiment Videos
Stereotactic radiosurgery for glioblastoma multiforme
J E Masciopinto1, A B Levin, M P Mehta
1Department of Neurological Surgery, University of Wisconsin Hospitals and Clinics, Madison, USA.
Stereotactic and Functional Neurosurgery
|January 1, 1994
Summary
Stereotactic radiosurgery (SR) combined with radiation therapy offers no survival benefit for glioblastoma multiforme patients. Recurrences commonly occurred outside the targeted SR area, suggesting limited efficacy for this primary treatment approach.
Area of Science:
- Neurosurgery
- Radiation Oncology
- Oncology
Background:
- Glioblastoma multiforme is an aggressive primary brain tumor.
- Standard treatment involves surgery and radiation therapy.
- The role of stereotactic radiosurgery (SR) as primary therapy requires investigation.
Purpose of the Study:
- To evaluate the efficacy of stereotactic radiosurgery (SR) as a component of primary therapy for glioblastoma multiforme.
- To assess the impact of SR on patient survival and recurrence patterns.
Main Methods:
- Retrospective analysis of 26 glioblastoma multiforme patients treated between 1989 and 1992.
- Patients underwent tumor debulking or biopsy, followed by SR and standard radiation therapy.
- Individualized SR planning using 3D software with specific collimator sizes and dose gradients.
Main Results:
- No significant survival differences were observed based on surgical approach (biopsy vs. debulking), SR isocenter number, age, or initial performance status.
- Radiographic recurrences were predominantly peripheral (16 patients) or distant (4 patients) to the central SR field; none occurred centrally.
- Predicted 12-month survival was 24%, with a median survival of 9.5 months, comparable to surgery and radiotherapy alone.
Conclusions:
- Stereotactic radiosurgery (SR) as a primary therapy for glioblastoma multiforme provides minimal to no improvement in survival or quality of life.
- Recurrence patterns indicate that SR's effectiveness is limited, with failures occurring outside the treated volume.
- Further research is needed to optimize treatment strategies for glioblastoma multiforme.